These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 11252344)
1. Sensitivity testing of Pseudomonas aeruginosa to ciprofloxacin: comparison of the modified Stokes' method with MIC results obtained by the Etest. Galloway A; Wright J; Murphy O; Dickinson G J Antimicrob Chemother; 1999 Feb; 43(2):314-5. PubMed ID: 11252344 [No Abstract] [Full Text] [Related]
2. In vitro activity of meropenem in combination with ciprofloxacin against clinical isolates of Pseudomonas aeruginosa. Solak S; Willke A; Ergönül O; Tekeli E Int J Antimicrob Agents; 2005 Feb; 25(2):181-2. PubMed ID: 15664492 [No Abstract] [Full Text] [Related]
3. Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime. Alyaseen SA; Piper KE; Rouse MS; Steckelberg JM; Patel R Antimicrob Agents Chemother; 2005 Jun; 49(6):2543-5. PubMed ID: 15917569 [TBL] [Abstract][Full Text] [Related]
4. [Comparison of standard proportion dilution test and Etest for Mycobacterium tuberculosis sensitivity to ofloxacin and ciprofloxacin]. Cavuşoğlu C; Ciçek-Saydam C; Burhanoğlu D; Ozkalay N; Ozkaya D; Ozçam H; Bilgiç A Mikrobiyol Bul; 2002 Jan; 36(1):118-23. PubMed ID: 12476777 [TBL] [Abstract][Full Text] [Related]
5. [Relationship between the sensitivity of Pseudomonas aeruginosa and the post-antibiotic effect of sparfloxacin and ciprofloxacin]. Pastor A; Cantón E; Pemán J Rev Esp Quimioter; 1998 Dec; 11(4):333-8. PubMed ID: 9990147 [TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317 [TBL] [Abstract][Full Text] [Related]
7. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus]. Cetinkaya E; Coban AY; Durupinar B Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076 [TBL] [Abstract][Full Text] [Related]
8. [Release of DNA from Pseudomonas aeruginosa in vitro during spontaneous growth and treatment with ciprofloxacin]. Peng DZ; Guymon CH; McManus AT; Xiao GX Zhonghua Wai Ke Za Zhi; 2005 Feb; 43(3):178-81. PubMed ID: 15842899 [TBL] [Abstract][Full Text] [Related]
10. Postantibiotic effect and virulence factors depression induced by ciprofloxacin and by aminoglycosides in a clinical isolate of Pseudomonas aeruginosa. Hostacka A Zentralbl Bakteriol; 1996 Mar; 283(3):322-7. PubMed ID: 8861870 [TBL] [Abstract][Full Text] [Related]
11. Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation. Prabhu RM; Elliott MA; Patel R Clin Infect Dis; 2004 Apr; 38(7):1043-5. PubMed ID: 15034845 [No Abstract] [Full Text] [Related]
12. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. Burgess DS; Hall RG Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693 [TBL] [Abstract][Full Text] [Related]
13. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Lee JK; Lee YS; Park YK; Kim BS Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307 [TBL] [Abstract][Full Text] [Related]
14. Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin. Wolter DJ; Schmidtke AJ; Hanson ND; Lister PD Antimicrob Agents Chemother; 2007 Aug; 51(8):2997-3000. PubMed ID: 17517839 [TBL] [Abstract][Full Text] [Related]
15. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media. Jang CH; Park SY Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):321-3. PubMed ID: 15270816 [TBL] [Abstract][Full Text] [Related]
17. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Pasquali F; Manfreda G Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619 [TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of ciprofloxacin against immobilized Pseudomonas aeruginosa. Konrad-Dalhoff I; Dalhoff A Chemioterapia; 1987 Jun; 6(2 Suppl):137-8. PubMed ID: 3151334 [No Abstract] [Full Text] [Related]
19. Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa. Brazas MD; Hancock RE Antimicrob Agents Chemother; 2005 Aug; 49(8):3222-7. PubMed ID: 16048929 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Etest with agar dilution for testing the susceptibility of Pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin. Goldstein FW; Ly A; Kitzis MD J Antimicrob Chemother; 2007 May; 59(5):1039-40. PubMed ID: 17437963 [No Abstract] [Full Text] [Related] [Next] [New Search]